- Home
- CVKD vs ANEB Comparison
CVKD vs ANEB Comparison
Compare CVKD & ANEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CVKD | ANEB |
|---|---|---|
| Founded | 2022 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.7M | 46.0M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CVKD | ANEB |
|---|---|---|
| Price | $7.17 | $1.03 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $32.00 | N/A |
| AVG Volume (30 Days) | 85.1K | ★ 126.1K |
| Earning Date | 11-10-2025 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.42 | $0.90 |
| 52 Week High | $22.90 | $3.42 |
Technical Indicators
Market Signals| Indicator | CVKD | ANEB |
|---|---|---|
| Relative Strength Index (RSI) | 37.68 | 23.04 |
| Support Level | $6.42 | $0.91 |
| Resistance Level | $7.62 | $1.25 |
| Average True Range (ATR) | 0.84 | 0.19 |
| MACD | -0.08 | -0.10 |
| Stochastic Oscillator | 11.84 | 11.73 |
Price Performance
Historical ComparisonAbout CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.